Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

A 10-day course of oral fidaxomicin (200 mg twice a day [b.i.d.]), a potent new macrocyclic drug, was compared to vancomycin (125 mg four times a day [q.i.d.]) in 1,164 adults (1,105 in the modified intent-to-treat [mITT] population) with Clostridium difficile infection in two phase III randomized,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Goldstein, Ellie J. C., Citron, Diane M., Sears, Pamela, Babakhani, Farah, Sambol, Susan P., Gerding, Dale N.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2011
Matèries:
Susceptibility
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3195051/
https://ncbi.nlm.nih.gov/pubmed/21844318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00625-11
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars